<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Classification of inherited von Willebrand disease (VWD)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Classification of inherited von Willebrand disease (VWD)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Classification of inherited von Willebrand disease (VWD)</div><div class="cntnt"><table cellspacing="0"><colgroup span="4" width="25%"></colgroup> <tbody> <tr> <td class="subtitle1">Type</td> <td class="subtitle1">Clinical features</td> <td class="subtitle1">Laboratory findings</td> <td class="subtitle1">Comments on treatment</td> </tr> <tr class="divider_bottom"> <td><strong>Type 1 (partial quantitative deficiency)</strong></td> <td> <ul> <li>Accounts for approximately 75% of individuals with VWD</li> <li>Variable bleeding severity from mild to severe</li> <li>AD inheritance</li> </ul> </td> <td> <ul> <li>VWF activity and antigen decreased concordantly</li> <li>Factor VIII activity normal or reduced</li> <li>RIPA decreased (may be normal in mild disease)</li> <li>Multimer electrophoresis: All multimers present and uniformly decreased</li> <li>In type 1C (increased clearance), the VWF level at 4 hours post DDAVP trial shows rapid reduction in VWF</li> </ul> </td> <td> <ul> <li>DDAVP* in most patients</li> <li>VWF concentrates in moderate, severe, and type 1C patients</li> </ul> </td> </tr> <tr> <td colspan="4"><strong>Type 2 (qualitative variant)</strong></td> </tr> <tr> <td class="indent1">Type 2A (selective deficiency of HMW multimers, reduced binding to platelet GPIb)</td> <td> <ul> <li>Accounts for approximately 10 to 20% of individuals with VWD</li> <li>Moderate to severe bleeding</li> <li>Mostly AD; occasional AR inheritance</li> </ul> </td> <td> <ul> <li>VWF activity decreased out of proportion to VWF antigen</li> <li>Factor VIII activity normal or reduced</li> <li>RIPA decreased</li> <li>Multimer electrophoresis: Large multimers decreased</li> </ul> </td> <td> <ul> <li>DDAVP*</li> <li>VWF concentrates in moderate and severe patients</li> <li>Follow VWF levels</li> </ul> </td> </tr> <tr> <td class="indent1">Type 2B (enhanced binding of HMW VWF multimers to platelet GPIb; may have decrease in circulating HMW multimers)</td> <td> <ul> <li>Accounts for approximately 5% of individuals with VWD</li> <li>Moderate to severe bleeding</li> <li>Thrombocytopenia</li> <li>AD inheritance</li> </ul> </td> <td> <ul> <li>VWF activity decreased out of proportion to VWF antigen</li> <li>Factor VIII activity normal or reduced</li> <li>Thrombocytopenia</li> <li>RIPA increased</li> <li>Multimer electrophoresis: Usually decreased large multimers</li> </ul> </td> <td> <ul> <li>DDAVP* should be used with caution; it may be used to treat minor bleeding if a trial of DDAVP performed when the patient is not bleeding has demonstrated that the platelet count drop is temporary</li> <li>VWF concentrates in moderate and severe patients</li> </ul> </td> </tr> <tr> <td class="indent1">Type 2M (reduced binding of VWF to platelet GPIb)</td> <td> <ul> <li>Uncommon</li> <li>Moderate to severe bleeding</li> <li>AD or AR inheritance</li> </ul> </td> <td> <ul> <li>VWF activity decreased out of proportion to VWF antigen</li> <li>Factor VIII activity normal or decreased</li> <li>RIPA decreased</li> <li>Multimer electrophoresis: All multimers present and uniformly decreased</li> </ul> </td> <td> <ul> <li>DDAVP*</li> <li>VWF concentrates in moderate and severe patients</li> </ul> </td> </tr> <tr class="divider_bottom"> <td class="indent1">Type 2N (reduced binding of VWF to factor VIII)</td> <td> <ul> <li>Uncommon</li> <li>Clinically similar to hemophilia A with joint, soft tissue, and urinary bleeding</li> <li>AR inheritance</li> </ul> </td> <td> <ul> <li>VWF activity and antigen normal</li> <li>Factor VIII levels low (5 to 15%)</li> <li>RIPA normal</li> <li>Multimer electrophoresis: Normal</li> </ul> </td> <td> <ul> <li>DDAVP*</li> <li>VWF concentrates</li> <li>Monitor VWF and factor VIII levels</li> </ul> </td> </tr> <tr> <td><strong>Type 3 (severe quantitative deficiency/absent VWF)</strong></td> <td> <ul> <li>Rare</li> <li>Clinically similar to hemophilia A with joint and soft tissue bleeding in addition to mucocutaneous bleeding</li> <li>AR inheritance</li> </ul> </td> <td> <ul> <li>VWF activity and antigen absent or markedly decreased</li> <li>Factor VIII levels low (1 to 10%)</li> <li>RIPA absent or very low</li> <li>Multimer electrophoresis: Undetectable or too faint to visualize</li> </ul> </td> <td> <ul> <li>VWF concentrates</li> <li>Factor VIII replacement</li> <li>Do <strong>not</strong> use DDAVP to treat bleeding (will not be effective)</li> </ul> </td> </tr> </tbody></table></div><div class="graphic_lgnd">This table summarizes types of inherited VWD. Acquired von Willebrand syndrome (AVWS) is an acquired condition (not genetically transmitted) that mimics inherited VWD; AVWS has various underlying causes. Refer to UpToDate for additional details of the presentation, diagnosis, and management of VWD and AVWS.</div><div class="graphic_footnotes"><p>VWD: von Willebrand disease; AD: autosomal dominant; VWF: von Willebrand factor; RIPA: ristocetin-induced platelet aggregation; DDAVP: desmopressin; HMW: high molecular weight; GPIb: platelet glycoprotein Ib; AR: autosomal recessive; AVWS: acquired von Willebrand syndrome.</p>
	
	* DDAVP should only be used after a therapeutic trial (when not bleeding) shows efficacy in raising VWF levels (or factor VIII levels in type 2N disease) to &gt;50%.</div><div class="graphic_reference">Adapted from:
	<ol>
<li>Sadler JE, Budde U, Eikenboom JCJ, et al. Update on the pathophysiology and classification of von Willebrand disease: A report of the Subcommittee on von Willebrand factor. J Thromb Haemost 2006; 4:2103.</li>
<li>The National Heart, Lung, and Blood Institute. The Diagnosis, Evaluation, and Management of Von Willebrand Disease. Bethesda, MD: National Institutes of Health Publication 08-5832, December 2007.</li>
<li>James PD, Connell NT, Ameer B, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. Blood Adv 2021; 5:280.</li>
</ol></div><div id="graphicVersion">Graphic 71525 Version 14.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
